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Background: In Kenya, malaria case management is based on clinical suspicion and detection of parasite in blood by 
parasitological or confirmatory diagnosis. Confirmatory diagnosis can be achieved with either microscopy or Rapid 
diagnostic tests (RDTs). RDTs are relatively new technologies, and their performance in actual conditions of use needs 
to be evaluated to provide information for appropriate use and to support decision making in procurement.  
Objectives: To evaluate performance and operational characteristics of three malaria RDTs: CareStart™, First 
Response®, and SD Bioline™ in the field for diagnosis of infection by Plasmodium falciparum monospecies as well as 
mixed infections with P. ovale and P. malariae.  
Methodology: A prospective study with blind comparisons to a gold standard was carried out at Pingilikani 
dispensary in Kilifi County, Kenya. Blood samples were obtained from 500 febrile children. Three RDTs: CareStart™, 
First Response® and SD Bioline™ were evaluated against microscopy of Giemsa stained blood films for detection of 
Plasmodium falciparum and non-falciparum malarial parasites. RDTs specific for P. falciparum only (HRP2 RDTs) and 
non-falciparum malarial parasites (HRP2/pLDH (Pf/pan) RDTs) were evaluated.   
Results: Plasmodium sp were detected by microscopy in 242 (48.40%) study participants. Plasmodium falciparum 
species were the most prevalent (93.3%) in comparison with other Plasmodium species: P. ovale and P. malariae 
whose prevalence were 2.89% and 3.71% respectively. Compared to microscopy the sensitivities of CareStart™, SD 
Bioline™, and First Response® RDTs for Plasmodium falciparum using Pf (mono species) kits were: 95.04% (95% CI: 
92.34 - 97.73), 95.04% (95% CI: 92.34 - 97.73) and 94.21% (95% CI: 91.3 - 97.11) respectively while the specificities 
were 78.12% (95% CI: 72.98 - 83.25), 81.10% (95% CI: 76.23 - 85.96) and 78.74%  (95% CI: 73.65 - 83.82) 
respectively. Sensitivities of CareStart™, SD Bioline™ and First Response® RDTs for Plasmodium falciparum using 
Pf/Pan kits were: 99.02% (95% CI: 98.92 - 99.15), 99.04% (95% CI: 98.92 – 99.15) and 97.56% (95% CI: 97.78 – 
97.99), respectively while the specificities were 78.46% (95% CI: 77.61 - 79.30), 78.46% (95% CI: 75.78 - 81.13) and 
80.28% (95% CI: 76.73 - 83.82) respectively. CareStart™, SD Bioline™, and First Response® RDTs for non-falciparum 
sp using Pf/Pan kits both had 100% sensitivity and specificity.  
Conclusion: Data from this study demonstrate that CareStart™, SD Bioline™ and First Response® RDTs have good 
operational characteristics and are reliable alternatives to microscopy for diagnosing malaria in children.  
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1. Introduction 
Malaria remains one of the leading causes of death in 
tropical and sub-tropical countries, particularly in 
Africa where 90% of malaria cases occur in children 
below the age of five years (WHO, 2013). WHO 
recommends that treatment of malaria be initiated after 
the diagnosis has been confirmed parasitologically by 
microscopy or rapid diagnostic tests (RDTs). In many 
instances, however, microscopy requires technical skills 
and equipment that are usually unavailable or 
inaccessible in most malaria endemic areas. This has 
spurred interest in developing rapid diagnostic 
strategies that will be effective including in resource-
limited areas where expertise in malaria diagnosis is 
often lacking (Reyburn et al, 2007; Bell et al, 2006). 
Evaluating performance characteristics of commercially 
available malaria RDTs have been conducted through 
Panel studies (WHO, 2013). Although these studies have 
provided selection criteria, field evaluations are 
essential to obtain operational data (Murray et al, 2008; 
Hopkins et al, 2008; Wongsrichanalai et al, 2007). 
The use of RDTs is preferable because they provide 
instant diagnosis and enables immediate treatment. 
Before rolling out large scale use of mono-Plasmodium 
species or multi-species malaria RDTs in endemic 
regions, choice of correct malaria RDTs should be 
influenced by the performance of the diagnostic 
strategy in the field. This study was aimed at evaluating 
performance characteristics of malaria rapid diagnostic 
tests (RDTs) for both mono and multi species in a 
malaria endemic region in coastal Kenya among 
children who are the most affected group in the 
population. 
2. Methods 
2.1 Study area  
This study was done during the malaria transmission 
season (May - July 2014) at Pingilikani dispensary, 
Chonyi area in Kilifi County, Kenya. The region is 
classified as a moderate to high transmission area. It 
has been estimated that residents of this area have 22-
53 infective bites per person per year (Mbogo et al, 
2003). In this study area the average prevalence of 
parasites in children less than one year old is 13.8% 
while in children between 1 and 9 years of age is 40.5% 
(Mwangi et al, 2005). 
2.2 Study design 
The design was a prospective hospital based study that 
involved blind comparisons of test results to a gold 
standard.  
2.3 Study population and Eligibility Criteria 
All children between the ages of 2 months and 13 years, 
who were febrile and with suspected malaria at 
Pingilikani Dispensary between 25th June 2014 and 6th 
August 2014 were eligible for the study. 
A minimal sample size of 200 patients was calculated 
sufficient to detect sensitivity, specificity and predictive 
values in patients with malaria at a two sided level of 
significance of 5% and 95 % level of confidence. 
Both male and female children between the ages of 2 
months and 13 years, who were febrile (defined as core 
body temperature ≥ 38.0°C or oral temperature > 
37.5°C) and with suspected malaria at Pingilikani 
Dispensary between 25th June 2014 and 6th August 2014 
were eligible for the study. Patients with severe clinical 
malaria symptoms such as convulsions were excluded. 
Patients were also excluded if consent was refused. 
2.4 Blood Collection 
Blood samples were obtained from febrile children, 
through finger pricking using Becton Dickinson (BD) 
contact-activated lancet, microscopy thick and thin 
films were prepared, and malaria RDTs testing was 
done. Patients with positive malaria RDTs results were 
treated with Artemisinin based Combination Therapy 
(ACT). 
2.5 Assessment of rapid diagnostic test kits  
The three malaria RDTs used in this study were 
procured from the manufacturers authorized sales 
representative in Kenya, that is, SAI pharmaceutical for 
CareStart, Value Diagnostics for SD Bioline and 
Intercross for First Response.  All tests were performed 
by laboratory technologists at Pingilkani Dispensary, 
applying the manufacturers’ instructions, and blinded 
as to microscopy results. HRP2 RDTs used in the study 
detect histidine-rich protein II expressed by P. 
falciparum. On the other hand pLDH (Pf/pan) RDTs 
detect plasmodium lactate dehydrogenase expressed by 
all plasmodium species. Consequently samples that 
were positive to HRP2 RDTs indicate P. falciparum 
infection. Samples that tested negative to HRP2 RDTs 
and positive to pLDH RDTs indicated non-falciparum 
infections; while those that tested positive to both HRP2 
and pLDH RDTs signalled P. falciparum or mixed 
infections. 
2.6 Microscopy 
Thick and thin blood films were prepared for each 
blood sample.  Thin films were prepared by smearing 
blood on a glass slide and fixing with methanol.  The 
blood smears were stained with 10% Giemsa stain for 
10 minutes and analyzed under the microscope at x 
1,000 magnification. A minimum of 200 consecutive 
fields in the thick blood film were counted before the 
slide was classified as negative. Parasites in thick blood 
film were counted against 200 white blood cells 
(WBCs). The parasite density per ml was estimated by 
assuming 8,000 WBC/μl of blood (Jeremiah and Uko, 
2007). Expert microscopists in the reference 
laboratory-Kenya Medical Research Institute/Wellcome 
Trust Research Programme - Kilifi (KEMRI/WTRP) 
were blinded to the RDT results. 
2.7 Data analysis 
Sensitivity, specificity, positive predictive values (PPV) 
and negative predictive values (NPV) and their 95% 
confidence intervals (CIs) were calculated. 95% 
confidence intervals were calculated using the formula 
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P ± 1.96 √P (1-P)/N, where P is the sensitivity or 
specificity, and N is the number of samples from 
participants infected with malarial parasites (or, for 
specificity, from uninfected participants).  Paired t test 
was used to calculate statistical significance at p<0.05.  
2.8 Ethical Consideration 
The study protocol was approved by Kenyatta National 
Hospital and University of Nairobi   Ethical Review 
Committee (Ref: P314/05/2014). Written informed 
consent was sought from each study participant before 
being enrolled in the study. Participant’s confidentiality 
was maintained. Children diagnosed with malaria were 
treated in accordance with the Kenya malaria treatment 
guidelines, that is, with artemisinin based combination 
therapy (ACT) for uncomplicated P. falciparum malaria 
while for non P. falciparum malaria (P. vivax and P. 
ovale) malaria, ACT treatment was supplemented with 
primaquine. 
3. Results  
General characteristics of the study population 
A total of 500 participants of both sexes between ages of 
2 months – 13years were recruited for this study 
between 25th June and 6th August 2014. There were 
more male participants (64%) compared to females 
(36%). Based on microscopy, majority [167 (69%)] of 
participants infected with malaria were children below 
the age of 5 years (Table 1).  
Distribution of participants by Age and Parasite 
Density 
Majority of participants [177 (73%)] had parasite 
density > 5000 Parasite / µl. Children who were 5 years 
old or below were more parasitaemic than those above 
5 yrs of age (p=0.016) (Table 2). 
 
 
Table 1: Disease burden in the study population  
   Positive by microscopy (n/%) Negative by microscopy (n)  
 Week > 5years 2 Months - 5 years > 5years 2 Months - 5 years TOTAL 
1 25 46 9 40 120 
2 20 31 15 54 120 
3 8 18 5 10 41 
4 15 50 20 40 125 
5 7 22 29 36 94 
Female 
Male 
Total 
34 (14%) 
41 (17%) 
75 (31%) 
63 (26%) 
104 (43%) 
167 (69%) 
30 
48 
78 
53 
127 
180 
180 (36%) 
320 (64%) 
500 
 
Table 2: Distribution of participants by Age and Parasite Density 
  Parasite / µl 
Age ≤ 100 101 - 200 201 – 500 501 – 1000 1001 - 5000 5001 - 50,000 > 50,000 Total 
2 Months - 5 years 1 2 6 9 21 81 46 166 
 > 5years 0 0 5 3 18 25 25 76 
Totals 1 2 11 12 39 106 71 242 
 
 
Performance characteristics of kits detecting 
Plasmodium falciparum HRP2 antigen 
Compared to the reference standard, the sensitivities of 
SD Bioline™,  First Response and . CareStart™ were 
95.04 %, 94.21 % and 95.04% respectively. The 
specificities were  81.10%, 78.74% and 78.12% 
respectively. The positive predictive values of the three 
tests were 82.73%, 80.85% and 80.41% respectively, 
while the negative predictive values were 94.49 %, 
93.45% and 94.33% respectively (Table 3). 
Performance characteristics of RDTs detecting 
Plasmodium HRP2/pLDH antigens 
For Plasmodium falciparum, the sensitivity, specificity, 
PPV, NPV of SD Bioline was 99.04 %, 78.46 %, 78.78%  
and 99.02 % respectively whereas First Response® had 
97.56 % sensitivity, 80.28 % specificity, 74.07 % PPV, 
98.27 % NPV. CareStart™ had sensitivity, specificity, 
PPV, NPV of 99.02 %, 78.46%, 78.46% and 99.02 % 
respectively (Table 4). 
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Table 3: Performance characteristics of three different RDTs in detecting P. falciparum HRP2. 
 Microscopy 
HRP2 (Pf) 
CareStart™ SD Bioline™ First Response® 
P. falciparum 121 143 139 142 
Plasmodium species*  1 - - - 
Mixed infection 0 0 0 0 
Total Positive 122 143 139 142 
Total Negative 128 107 110 108 
Total No. of samples 250 250 249 249 
Pf sensitivity %  (95% CI)   95.04 (92.34 - 97.73) 95.04  (92.34 - 97.73) 94.21  (91.3 - 97.11) 
Specificity %  (95% CI)  78.12  (72.98 - 83.25) 81.10  (76.23 - 85.96) 78.74  (73.65 - 83.82) 
PPV % (95% CI)  80.41  (75.48 - 85.33) 82.73  (78.03 - 87.42) 80.85  (75.96 - 85.73) 
NPV  (95% CI)  94.33  (91.45 - 97.20) 94.49  (91.65 - 97.32) 93.45 (90.37 - 96.52) 
CI - Confidence Interval, PPV - Positive Predictive value, NPV - Negative Predictive Value 
Invalid test – (1) SD Bioline, (1) First Response; *plasmodium species ref (P. malariae and P. ovale)  
 
Table 4: Performance characteristics of three different RDTs in detecting Plasmodium HRP2/pLDH antigens 
 
Microscopy 
HRP2/pLDH (Pf/Pan) 
Carestart™ (N) SD Bioline™ (N) First Response® (N) 
P. falciparum 105 130 132 54 
Plasmodium species* 15 15 15 7 
Mixed infection 0 0 0 0 
Total Positive 120 145 147 61 
Total Negative 130 103 103 58 
Total No. of samples 250 248 250 119 
Pf sensitivity (%) (95% CI)  99.02 (98.92 - 99.15) 99.04 (98.92 – 99.15) 97.56 (97.78 – 97.99) 
Pan sensitivity (%) (95% CI)  100 100 100 
Total sensitivity (%)  99.51 99.52 98.78 
Specificity %  (95% CI)  78.46 (77.61 - 79.30) 78.46 (75.78 - 81.13) 80.28 (76.73 - 83.82) 
PPV % (95% CI)  78.46 (77.61 - 79.30) 78.78 (76.14 - 81.41) 74.07 (69.41 - 78.72) 
NPV  (95% CI)  99.02 (98.89 - 99.14) 99.02 (98.89 - 99.14) 98.27 (97.95 - 98.58) 
CI - Confidence Interval, PPV - Positive Predictive value, NPV - Negative Predictive Value 
Invalid tests – (2) CareStart, (1) First Response; *P. malariae and P. Ovale.  
The sensitivity, specificity, PPV, NPV of all the three kits 
in detecting non falciparum species was 100%. The 
number of non falciparum species detected in this area 
using the Pf/Pan kits was low (15) so it may not reflect 
actual performance of the Pf/Pan kits. The non-
falciparum malaria parasites identified were P. malariae 
(3.71%) and P. ovale (2.89%) (Table 4). In total 
Microscopic analysis showed that 226 (93.3%) blood 
slides were positive for P. falciparum while 9 were 
positive for P. malariae (3.71%) and 7 were positive for 
P. ovale (2.89%). All the three kits had sensitivities of 
100% at parasite densities > 5000 Parasite / μl. 
However sensitivities  were variable  (89 - 95 %) at 
parasite densities <5000 Parasite /μl.  
4.0 Discussion 
In this study, three malaria RDTs: SD Bioline™; 
CareStart™ and First Response® were evaluated for 
their performance in diagnosis of malaria in children in 
comparison to Giemsa stain microscopy as a reference 
standard. Our findings demonstrate that SD Bioline™; 
CareStart™ and First Response® are reliable 
alternatives to Giemsa stain microscopy, with SD 
Bioline™ and CareStart™ HRP2 RDTs having 
sensitivities ≥ 95% while First Response® had a 
sensitivity of 94.2%. Higher sensitivity trends were 
observed with HRP2/pLDH (Pf/pan) RDTs (SD 
Bioline™, 99.04%; CareStart™, 99.02%; First 
Response®, 97.56%).  
The findings are consistent with previous studies in 
other parts of the world such as central Asia (Singh et al, 
2013). The results of the study also compare well with 
the findings of WHO product performance evaluations 
using cultured P. falciparum and frozen samples (WHO, 
2013). Sensitivity can be influenced by the low numbers 
of the parasite. In round 5 of the WHO report (2013), 
First Response Pf, CareStart Pf and SD Bioline Pf had 
high panel detection score for the diagnosis of 
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Plasmodium falciparum malaria at 95%, 91% and 95%, 
respectively, when at least 200 parasites/ µl were 
present. This compares to sensitivity results obtained in 
this study at ≤200 parasite /µl, 100% for SD Bioline Pf, 
100% CareStart Pf and 100% First Response. However 
the comparisons between the WHO evaluation data and 
those from the present study is limited by the fact that 
the WHO evaluation and analysis included samples with 
fixed  parasite densities whereas the present study had 
variable range of parasite densities. 
Recent performance evaluation of malaria RDTs has 
mainly focused on the detection of Plasmodium 
falciparum and other malaria species (P. ovale, P. 
malariae and P. vivax). In this study falciparum malaria 
detection accounted for 93.3% compared to non-
falciparum malaria 6.7%. The non-falciparum malaria 
parasites identified were P. malariae (3.71%) and P. 
ovale (2.89%).  
Although the three RDTs (SD Bioline, CareStart and 
First response) can detect malaria cases at parasitaemia 
levels of >200 parasites/μl, the product performances 
has been shown to be variable at low parasitaemia 
(WHO, 2011). In this study the SD Bioline; CareStart and 
First Response kits had sensitivities of 100% at parasite 
densities > 5000 parasite/μl.  However, sensitivities 
were variable at parasite densities < 5000 parasite/µl. It 
is further observed that while RDTs for P. falciparum 
detected parasites at low parasite densities, the RDTs 
for non-falciparum species failed to detect parasites at 
low density. This indicates that confirmatory diagnosis 
of non-falciparum malaria in cases of low parasite 
densities should be backed up by microscopy or 
alternative methods.  
Equally, the failure of RDTs to detect high parasite 
density has been observed in other studies (Palmer et 
al, 1998; Dyer et al, 2000). In this study there were 
some instances where the HRP2 RDTs failed to detect 
high level of parasite density (1000-5000 parasites/μl). 
This could be explained by parasite genetic variability. 
Kumar et al (2012) showed that genetic variation in 
Plasmodium falciparum HRP can be the possible cause 
of variability in sensitivity. Another study showed that a 
small number of Plasmodium falciparum do not express 
the HRP-2 due to mutations or deletions of the hrp-2 
gene leading to false negative RDT results (Koita et al, 
2012). False negative tests have also been observed to 
be as a result of prozone effect - excess antibodies or 
antigens (Gillet et al, 2009; Luchavez et al, 2011). 
Concerns over differences in performance of RDTs have 
previously been raised (WHO, 2011b). Performance 
variability has been attributed to the manufacturing 
process of the kits. In this study low specificity to 
Plasmodium falciparum (HRP2) observed was as a 
result of high number of false positives. One of the 
limitations of RDTs in detection of Plasmodium 
falciparum histidine-rich protein 2 (HRP-2) is the time it 
takes to eliminate the proteins in the blood. It has been 
documented that 28 days after effective treatment with 
antimalarial drugs, HRP-2 antigens could be detected in 
blood (Wongsrichanalai et al, 2007; Tijra et al, 2001).  
In this study presence of false positive results was 
observed in some patients who had malaria therapy less 
than 3 weeks prior to enrolment into the study. 
Presence of false positives RDTs results leads to wrong 
diagnosis, wastage of drugs and inappropriate use of 
antimalarial treatments and hence the development of 
drug resistance. Increase in the number of false 
positives has also been shown to be as a result of 
limitation of microscopy in detecting low parasitaemia 
hence more accurate results would be expected if PCR 
was used as the reference standard (Bell et al, 2005; 
Hopkins et al, 2005).  
One important area that needs to be considered in 
evaluating performance characteristics of RDTs is 
number of days after effective treatment that a positive 
RDT result can be considered to be new malaria 
infection. This was beyond the scope of this study and is 
therefore not covered in the report. There is also need 
to evaluate heat stability of the RDTs in the field, and 
the outcome of site studies would be critical in 
informing policy with regard to procurement. 
5.0 Conclusion  
Malaria RDTs performance data from this study 
demonstrate that CareStart™, SD Bioline™ and First 
Response® RDTs  are reliable alternatives to 
microscopy for diagnosis malaria in children in malaria 
endemic regions such as coastal Kenya. The three RDTs 
can also be routinely deployed for malaria detection in 
the field to compliment the microscopy procedure. 
 
Conflict of Interest declaration 
The authors declare no conflict of interest.  
Acknowledgements 
We would like to thank the staff of Kenya Medical 
Research Institute/Wellcome Trust Research 
Programme - Kilifi (KEMRI/WTRP) for technical 
support. The Kenya National Alliance Against Malaria 
(KeNAAM) provided financial support. 
 
References 
Bell D, Wongsrichanalai C and Barnwell JW (2006). Ensuring 
quality and access for malaria diagnosis: how can it be 
achieved? Nat. Rev. Microbiol. 4: S7-S20. 
Bell DR, Wilson DW and Martin LB (2005).  False positive 
results of a Plasmodium falciparum histidine rich protein 2 
detecting malaria rapid diagnostic test due to high sensitivity 
in a community with fluctuating low parasite density. Am. J. 
Trop. Med. Hyg. 73:199-203. 
Craig MH, Bredenkamp BL, Williams CH, Rossouw EJ, Kelly VJ, 
Kleinschmidt I, Martineau A and Henry GF (2002). Field and 
laboratory comparative evaluation of ten rapid diagnostic 
tests. Trans. R. Soc. Trop. Med. Hyg. 96:258-265. 
Dyer ME, Tjitra E, Currie BJ and Anstey NM (2000). Failure of 
'pan malarial' antibody of the ICT malaria Pf/Pv 
immunochromatographic test to detect symptomatic 
Plasmodium malariae infection. Trans. R. Soc. Trop. Med Hyg.  
94:518. 
Osanjo et al, Afr. J. Pharmacol. Ther. 2017. 6(2): 77-82 
 
A KeSoBAP Publication ©2017. All rights reserved. 
82 
Gillet P, Mori M, Van Esbroeck M, Van den Ende J and Jacobs J 
(2009). Assessment of the prozone effect in malaria rapid 
diagnostic tests. Malar. J. 8: 271. 
Hopkins H, Bebell L, Kambale W, Dokomajilar C, Rosenthal PJ 
and Dorsey G (2008). Rapid diagnostic tests for malaria at 
sites of varying transmission intensity in Uganda. J. Infect. Dis. 
197: 510-518. 
Hopkins L (2011). Blood transfer devices for malaria rapid 
diagnostic tests: evaluation of accuracy, safety and ease of use. 
Malaria J. 10:30. 
Jeremiah ZA and Uko EK (2007). Comparative analysis of 
malaria parasite density using actual and assumed white 
blood cell counts. Annals Trop. Paed. 27:75-79. 
Kilian AH, Metzger WG, Mutschelknauss EJ, Kabagambe G, 
Langi P, Korte R and  von Sonnenburg F (2000). Reliability of 
malaria microscopy in epidemiological studies: results of 
quality control. Trop. Med. Int. Health. 5:3-8. 
Koita OA, Doumbo OK, Ouattara A, Tall LK, Konaré A, Diakité 
M, Diallo M, Sagara I, Masinde GL, Doumbo SN, Dolo A, 
Tounkara A, Traoré I and Krogstad DJ (2012). False-negative 
rapid diagnostic tests for malaria and deletion of the histidine-
rich repeat region of the hrp2 gene. Am. J. Trop. Med. Hyg. 
2:194-8. 
Kumar N, Singh JP, Pande V, Mishra N, Srivastava B, Kapoor R, 
Valecha N and Anvikar AR (2012). Genetic variation in 
histidine rich proteins among Indian Plasmodium falciparum 
population: possible cause of variable sensitivity of malaria 
rapid diagnostic tests. Malaria J. 11:298. 
Leke RFG, Djokam RR, Mbu R, Leke RJ, Fogako J, Megnekou R, 
Metenou SG and Zhou Y (1999). Detection of the Plasmodium 
antigens histidine rich protein2 in blood of pregnant women: 
implications for diagnosing placental malaria. J. Clin. Microbiol. 
37: 2992-2996. 
Luchavez J, Baker J, Alcantara S, Belizario V, Cheng Q, 
McCarthy JS and Bell D (2011). Laboratory demonstration of a 
prozone-like effect in HRP2-detecting malaria rapid diagnostic 
tests: implications for clinical management. Malaria J. 10: 286. 
Mbogo CM, Mwangangi JM, Nzovu J, Githure JI, Yan G and Beier 
JC (2003). Spatial and temporal heterogeneity of Anopheles 
mosquitoes and Plasmodium falciparum transmission along 
the Kenyan coast. Am. J. Trop. Med. Hyg. 68:734-42. 
Murray CK, Gasser RA Jr, Magill AJ and Miller RS (2008). 
Update on rapid diagnostic testing for malaria. Clin. Microbiol. 
Rev. 21:97-110. 
Mwangi TW, Mohammed M, Dayo H, Snow RW and Marsh K. 
(2005). Clinical algorithms for malaria diagnosis lack utility 
among people of different age groups. Trop. Med. Int. Health. 
10:530-536. 
Palmer CJ, Lindo JF, Klaskala WI, Quesada JA, Kaminsky R, 
Baun MK and Ager AL (1998). Evaluation of the OptiMAL test 
for rapid diagnosis of Plasmodium vivax and Plasmodium 
falciparum malaria. J. Clin. Microbiol. 36:203-206. 
Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, 
Drakeley C and Whitty CJ (2007). Rapid diagnostic tests 
compared with malaria microscopy for guiding outpatient 
treatment of febrile illness in Tanzania: randomised trial. BMJ 
334:403. 
Singh N, Bharti PK, Singh MP, Mishra S, Shukla MM, Sharma RK 
and Singh RK (2013). Comparative evaluation of bivalent 
malaria rapid diagnostic tests versus traditional methods in 
field with special reference to heat stability testing in central 
India. PloS One. 8:e58080. 
Tjitra E, Suprianto S, McBroom J, Currie BJ and Anstey NM 
(2001). Persistent ICT malaria P.f/P.v pan malarial and HRP2 
antigen reactivity after treatment of Plasmodium falciparum 
malaria is associated with gametocytemia and results in false-
positive diagnoses of Plasmodium vivax in convalescence. J. 
Clin. Microbiol. 39: 1025-1031. 
Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A and 
Wernsdorfer WH (2007). A review of malaria diagnostic tools: 
microscopy and rapid diagnostic test (RDT). Am. J. Trop. Med. 
Hyg. 77: 119-127. 
World Malaria Report (2009). Geneva, World Health 
Organization, 2009. 
World Health Organization (WHO) (2011). Malaria Rapid 
Diagnostic test performance: result of WHO product testing of 
malaria RDTs round 3 (2010-2011). 
www.who.tdr/publications/documents/rdt3.pdf.   
World Health Organization (WHO): RDT evaluation 
programme.  
www.wpro.who.int/malaria/sites/rdt/who_rdt_evaluation/2
013 
 
